Literature DB >> 12072950

In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.

G Prats1, C Roig, E Miró, F Navarro, B Mirelis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12072950     DOI： 10.1007/s10096-002-0709-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  9 in total

1.  In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

Authors:  D Felmingham; M J Robbins; K Ingley; I Mathias; H Bhogal; A Leakey; G L Ridgway; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  In vivo evaluation of NM441, a new thiazeto-quinoline derivative.

Authors:  M Ozaki; M Matsuda; Y Tomii; K Kimura; J Segawa; M Kitano; M Kise; K Shibata; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  In vitro antibacterial activity of a new quinolone, NM394.

Authors:  M Ozaki; M Matsuda; Y Tomii; K Kimura; K Kazuno; M Kitano; M Kise; K Shibata; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; Y Okuyama; A Morino; M Ozaki; Y Takebe
Journal:  J Clin Pharmacol       Date:  1994-09       Impact factor: 3.126

5.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors:  T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.

Authors:  T Yoshida; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  9 in total
  9 in total

1.  Penetration of orally administered prulifloxacin into human lung tissue.

Authors:  Ercole Concia; Benedetta Allegranzi; Giovanni B Ciottoli; Giovanna Orticelli; Marcello Marchetti; Paolo Dionisio
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial Drugs.

Authors:  Manjula Mehta; Jyoti Sharma; Sonia Bhardwaj
Journal:  Open Access Maced J Med Sci       Date:  2016-01-25

3.  Prulifloxacin.

Authors:  Susan J Keam; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.

Authors:  D E Karageorgopoulos; S Maraki; A C Vatopoulos; G Samonis; G C Schito; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-19       Impact factor: 3.267

5.  Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.

Authors:  Thomas R Fritsche; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

6.  Penetration of orally administered prulifloxacin into human prostate tissue.

Authors:  Claudio Giberti; Fabrizio Gallo; Maria T Rosignoli; Alessandro Ruggieri; Simona Barattè; Rossella Picollo; Paolo Dionisio
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure.

Authors:  Fabio Ghezzi; Maurizio Serati; Antonella Cromi; Stefano Uccella; Stefano Salvatore; Pierfrancesco Bolis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-21

8.  Cefixime versus prulifloxacin as a prophylactic treatment for prostate biopsy: a randomized study.

Authors:  Michael Samarinas; Konstantinos Skriapas; Iraklis Mitsogiannis; Stavros Gravas; Anastasios Karatzas; Vasileios Tzortzis
Journal:  Cent European J Urol       Date:  2020-10-10

Review 9.  Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.

Authors:  Francesco Blasi; Stefano Aliberti; Paolo Tarsia; PierAchille Santus; Stefano Centanni; Luigi Allegra
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.